Skip to main content

Table 3 The secondary end points in the two groups

From: Qing-Yi decoction in participants with severe acute pancreatitis: a randomized controlled trial

 

Test group (n = 46)

Control group (n = 39)

P value

Organ complications

   

Heart failure, n (%)‡

12 (26.1)

12 (30.8)

0.633

Duration of heart failure, days median (interquartile range)§

0 (0–1)

0 (0–2)

0.449

Respiratory failure, n (%)‡

28 (60.9)

20 (51.3)

0.374

Duration of respiratory failure, days median (interquartile range)§

1 (0–3)

1 (0–3)

0.835

ARF, n (%)‡

5 (10.9)

3 (7.7)

0.617

Duration of ARF, days median (interquartile range)§

0 (0–0)

0 (0–0)

0.715

Hepatic failure, n (%)‡

11 (23.9)

15 (38.5)

0.147

Duration of hepatic failure, days median (interquartile range)§

0 (0–0.3)

0 (0–4)

0.069

Paralytic ileus, n (%)‡

44 (95.7)

34 (87.2)

0.157

Duration of paralytic ileus, days median (interquartile range)§

4 (2–6)a

6 (4–8)

0.014

Infection, n (%)‡

6 (13.0)a

14 (35.9)

0.013

ICU stay, days median (interquartile range)§

0 (0–0)

0 (0–0)

0.209

Use of respirator, n (%)‡

4 (8.7)

9 (23.1)

0.066

Use of respirator, days median (interquartile range)§

0 (0–0)

0 (0–0)

0.067

  1. ‡Chi-square test, §Wilcoxon rank sum test. a P < 0.05 vs. control group
  2. ARF acute renal failure
  3. ICU intensive care unit